TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ANTICOAGULATION THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 EUROPE ANTICOAGULATION THERAPY MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING PREVALENCE OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM
3.1.2 INCREASING USAGE OF NOACS AS ALTERNATIVES TO WARFARIN
3.1.3 GROWING NUMBER OF SURGERIES
3.1.4 NUMBER OF PATIENTS REQUIRING LIFELONG ANTICOAGULATION THERAPY
3.2 RESTRAINTS
3.2.1 INCREASING GOVERNMENT RESTRICTION
3.2.2 PRODUCT RECALLS
3.2.3 HIGH COST OF DRUG DEVELOPMENT
3.3 OPPORTUNITIES
3.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
3.3.2 INCREASING DEVELOPMENTS IN BIOENGINEERING:
3.4 CHALLENGES
3.4.1 PATENT EXPIRY
3.4.2 SIDE-EFFECTS OF HEPARIN
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EUROPE ANTICOAGULATION THERAPY MARKET, BY PIPELINE ANALYSIS
6.1 OVERVIEW
7 EUROPE ANTICOAGULATION THERAPY MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 DEEP VEIN THROMBOSIS (DVT)
7.3 PULMONARY EMBOLISM (PE)
7.4 ARTERIAL THROMBOEMBOLISM (AT)
7.5 STROKE
7.6 OTHERS
8 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS
8.1 OVERVIEW
8.2 NOVEL ORAL ANTICOAGULANTS (NOAC)
8.2.1 FACTOR XA INHIBITORS
8.2.2 DIRECT THROMBIN INHIBITORS
8.2.3 ANTITHROMBIN PROTEIN THERAPEUTICS
8.3 HEPARIN
8.3.1 UNFRACTIONATED HEPARIN
8.3.2 LOW MOLECULAR WEIGHT HEPARINS (LMWH)
8.3.3 ULTRA LOW MOLECULAR WEIGHT HEPARINS (ULMWH)
8.4 VITAMIN K ANTAGONISTS
8.4.1 WARFARIN
8.4.2 COUMARINS
8.5 OTHERS
9 EUROPE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BIVALIRUDIN
9.3 DABIGATRAN
9.4 EDOXABAN
9.5 BETRIXABAN
9.6 RIVAROXABAN
9.7 APIXABAN
9.8 ENOXAPARIN
9.9 DALTEPARIN
9.10 OTHERS
10 EUROPE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INJECTABLE
10.3.1 SUBCUTENEOUS
10.3.2 INTRAVENOUS
10.3.3 INTRAPERITONEAL
10.3.4 OTHERS
11 EUROPE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA
11.1 OVERVIEW
11.2 CARDIOVASCULAR DISEASES
11.2.1 CORONARY ARTERY DISEASES
11.2.2 MYOCARDIAL INFARCTION
11.2.3 CARDIAC ARRHYTHMIA
11.3 ONCOLOGY
11.4 RESPIRATORY
11.5 NEPHROLOGY
11.6 CNS
11.7 OTHERS
12 EUROPE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE
12.1 OVERVIEW
12.2 PRE-SURGICAL PROCEDURES
12.3 POST SURGICAL PROCEDURES
12.4 KIDNEY DIALYSIS
12.5 HEART VALVE REPLACEMENT
13 EUROPE ANTICOAGULATION THERAPY MARKET, BY TYPE
13.1 OVERVIEW
13.2 GENERICS
13.3 BRANDED
13.3.1 ELIQUIS
13.3.2 XARELTO
13.3.3 PRADAXA
13.3.4 LOVENOX
13.3.5 OTHERS
?
14 EUROPE ANTICOAGULATION THERAPY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 CLINICS
14.4 HOMECARE
14.5 AMBULATORY SURGICAL CENTERS
14.6 OTHERS
15 EUROPE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACIES
16 EUROPE ANTICOAGULATION THERAPY MARKET, BY GEOGRAPHY
16.1 EUROPE
16.1.1 GERMANY
16.1.2 FRANCE
16.1.3 ITALY
16.1.4 U.K.
16.1.5 SPAIN
16.1.6 SWITZERLAND
16.1.7 RUSSIA
16.1.8 NETHERLANDS
16.1.9 BELGIUM
16.1.10 TURKEY
16.1.11 REST OF EUROPE
17 EUROPE ANTICOAGULATION THERPAY MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
18.1 STRENGTH
18.1.1 SIGNIFICANT INCREASE IN SHARES IN THE MARKET-FOCUSED SEGMENT
18.1.2 ESTABLISHED PRESENCE IN MARKET
18.2 WEAKNESS
18.2.1 DEPENDENCY ON THIRD-PARTY SUPPLIER
18.3 OPPORTUNITY
18.3.1 STRATEGIC INVESTMENTS /ACQUISITION/ PARTNERSHIPS / PRODUCT LAUNCH/ APPROVALS
?
18.4 THREAT
18.4.1 COMPLEXITY AND STRINGENT REQUIREMENTS FOR THE DRUG APPROVAL
18.5 DATA BRIDGE MARKET RESEARCH ANALYSIS
19 COMPANY PROFILES
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 GEOGRAPHICAL PRESENCE
19.1.5 PRODUCT PORTFOLIO
19.1.6 RECENT DEVELOPMENT
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 GEOGRAPHICAL PRESENCE
19.2.5 PRODUCT PORTFOLIO
19.2.6 RECENT DEVELOPMENTS
19.3 BAYER AG
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 GEOGRAPHICAL PRESENCE
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENTS
19.4 JOHNSON & JOHNSON SERVICES, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 GEOGRAPHICAL PRESENCE
19.4.5 PRODUCT PORTFOLIO
19.4.6 RECENT DEVELOPMENTS
19.5 SANOFI
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 GEOGRAPHICAL PRESENCE
19.5.5 PRODUCT PORTFOLIO
19.5.6 RECENT DEVELOPMENT
19.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHICAL PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENT
19.7 ASPEN HOLDINGS
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHICAL PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPMENTS
19.8 CIPLA INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHICAL PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPMENT
19.9 DAIICHI SANKYO COMPANY, LIMITED
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHICAL PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPMENTS
19.10 EAGLE PHARMACEUTICALS, INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 EISAI CO., LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHICAL PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENT
19.12 ENDO PHARMACEUTICALS INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHICAL PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENT
19.13 F. HOFFMANN-LA ROCHE LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHICAL PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
19.14 FRESENIUS KABI AG
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHICAL PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPMENTS
19.15 HIKMA PHARMACEUTICALS PLC
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHICAL PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPMENT
19.16 MITSUBISHI TANABE PHARMA CORPORATION.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHICAL PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPMENT
19.17 MYLAN N.V.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHICAL PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPMENTS
19.18 NOVARTIS AG
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHICAL PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPMENT
?
19.19 PORTOLA PHARMACEUTICALS, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.20 SHANGHAI FOSUN PHARMACEUTICAL (GROUP)CO. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHICAL PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPMENT
19.21 TARO PHARMACEUTICAL INDUSTRIES LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHICAL PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPMENT
19.22 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHICAL PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPMENTS
20 REFERENCES
21 QUESTIONNAIRE
22 RELATED REPORTS